Its flagship product, Tarceva, is an oral, once-a-day, small molecule inhibitor of the epidermal growth factor receptor.
The company also markets Novantrone for the approved oncology indications; and Gelclair for the relief of pain associated with oral mucositis.
Its other drug candidates include OSI-7904L, a liposomal formulation of a potent thymidylate synthase inhibitor, which is in phase II study; OSI-461, an inhibitor of cGMP phosphodiesterases, which is in phase I dose optimization study; and OSI-930, a tyrosine kinase inhibitor, which is in preclinical research stage.
In addition, OSI Pharmaceuticals, through its collaborative drug discovery program, develops CP-547,632, which targets vascular endothelial growth factor receptor and is in Phase II and Phase I trials; CP-868,596 that targets tumor derived angiogenesis and is in Phase I trials; and CP-724,714, which is an oral inhibitor of epidermal growth factor receptor 2 and is in Phase I clinical trial.
Further, its subsidiary, Prosidion Limited, specializes in diabetes and obesity treatment in the United Kingdom.
The company has collaboration agreements with Pfizer, Inc.; Cold Spring Harbor Laboratory; EiRX Therapeutics plc; Genentech, Inc.; and Roche.
OSI Pharmaceuticals is headquartered in Melville, New York.
